Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Apr, 2016 | Pages:
141 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H1 2016 Summary Global Markets Direct's, ‘Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H1 2016', provides an overview of the Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - The report reviews pipeline therapeutics for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) therapeutics and enlists all their major and minor projects - The report assesses Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Overview 9 Therapeutics Development 10 Pipeline Products for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Overview 10 Pipeline Products for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Comparative Analysis 11 Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Therapeutics under Development by Companies 12 Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Therapeutics under Investigation by Universities/Institutes 14 Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Products under Development by Companies 18 Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Products under Investigation by Universities/Institutes 20 Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Companies Involved in Therapeutics Development 21 Altor BioScience Corporation 21 APIM Therapeutics AS 22 Astellas Pharma Inc. 23 Bavarian Nordic A/S 24 BioCancell Ltd 25 Celgene Corporation 26 Cold Genesys, Inc. 27 Heat Biologics, Inc. 28 Spectrum Pharmaceuticals, Inc. 29 Taris Biomedical LLC 30 Telesta Therapeutics Inc. 31 UroGen Pharmaceuticals, Ltd. 32 Vakzine Projekt Management GmbH 33 Viralytics Ltd. 34 Viventia Bio Inc. 35 Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Therapeutics Assessment 36 Assessment by Monotherapy Products 36 Assessment by Target 37 Assessment by Mechanism of Action 39 Assessment by Route of Administration 41 Assessment by Molecule Type 43 Drug Profiles 45 ALT-801 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 ALT-803 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 apaziquone - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 APL-1202 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 ATX-101 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 BC-819 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Biologic for Superficial Bladder Cancer - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 cavatak - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 CG-0070 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 CV-301 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 DAB-389EGF - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 docetaxel - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 Drug for NMIBC - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 erlotinib hydrochloride - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 gemcitabine hydrochloride - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 imiquimod - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 lenalidomide - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 mitomycin SR - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 Monoclonal Antibody to Antagonize EGFR for Superficial Bladder Cancer - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 rAd-IFN - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 sirolimus albumin-bound - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 Urocidin - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 VB-4845 - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 vesigenurtucel-L - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 VPM-1002 - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Recent Pipeline Updates 95 Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Dormant Projects 131 Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Discontinued Products 132 Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Product Development Milestones 133 Featured News & Press Releases 133 Feb 25, 2016: Heat Biologics Provides Update on Its HS-410 Phase II Monotherapy Bladder Cancer Trial Arm 133 Feb 19, 2016: Spectrum Pharmaceuticals Announces FDA Acceptance of NDA Filing for EOquin (apaziquone for intravesical instillation) 133 Feb 10, 2016: FDA Lifts Heat Biologics Partial Clinical Hold 133 Feb 03, 2016: Heat Biologics Reports Update on Its HS-410 Phase 2 Bladder Cancer Trial 134 Jan 26, 2016: Heat Biologics CSO to Present Interim Results From the Monotherapy Arm in Its Ongoing HS-410 Phase 2 Bladder Cancer Trial at the Phacilitate Immunotherapy World Conference 134 Jan 13, 2016: UroGen Pharma Expands Uro-Oncology Clinical Pipeline with Addition of TLR-7 Agonist Phase 2 Asset 135 Nov 06, 2015: Heat Biologics Reports HS-410 Phase 1 Bladder Cancer Trial Results at the Society for Immunotherapy of Cancer Annual Meeting 135 Nov 03, 2015: Results of Heat Biologics' HS-410 Phase 1 Safety Trial in Non-Muscle Invasive Bladder Cancer to be Presented at SITC Annual Meeting 137 Oct 26, 2015: Spectrum Pharmaceuticals Initiates Apaziquone Pivotal Trial for the Treatment of Non-Muscle Invasive Bladder Cancer Following SPA Agreement 137 Aug 17, 2015: Spectrum Pharmaceuticals Announces Agreement with FDA on the Special Protocol Assessment (SPA) for the Upcoming Apaziquone Phase 3 Trial in Patients with Non-Muscle Invasive Bladder Cancer 138 Appendix 140 Methodology 140 Coverage 140 Secondary Research 140 Primary Research 140 Expert Panel Validation 140 Contact Us 140 Disclaimer 141
List of Tables
Number of Products under Development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), H1 2016 10 Number of Products under Development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 13 Number of Products under Investigation by Universities/Institutes, H1 2016 14 Comparative Analysis by Late Stage Development, H1 2016 15 Comparative Analysis by Clinical Stage Development, H1 2016 16 Comparative Analysis by Early Stage Development, H1 2016 17 Products under Development by Companies, H1 2016 18 Products under Development by Companies, H1 2016 (Contd..1) 19 Products under Investigation by Universities/Institutes, H1 2016 20 Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Altor BioScience Corporation, H1 2016 21 Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by APIM Therapeutics AS, H1 2016 22 Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Astellas Pharma Inc., H1 2016 23 Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Bavarian Nordic A/S, H1 2016 24 Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by BioCancell Ltd, H1 2016 25 Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Celgene Corporation, H1 2016 26 Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Cold Genesys, Inc., H1 2016 27 Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Heat Biologics, Inc., H1 2016 28 Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016 29 Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Taris Biomedical LLC, H1 2016 30 Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Telesta Therapeutics Inc., H1 2016 31 Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by UroGen Pharmaceuticals, Ltd., H1 2016 32 Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Vakzine Projekt Management GmbH, H1 2016 33 Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Viralytics Ltd., H1 2016 34 Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline by Viventia Bio Inc., H1 2016 35 Assessment by Monotherapy Products, H1 2016 36 Number of Products by Stage and Target, H1 2016 38 Number of Products by Stage and Mechanism of Action, H1 2016 40 Number of Products by Stage and Route of Administration, H1 2016 42 Number of Products by Stage and Molecule Type, H1 2016 44 Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics - Recent Pipeline Updates, H1 2016 95 Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Dormant Projects, H1 2016 131 Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Discontinued Products, H1 2016 132
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
